Advances in Therapy最新文献

{"title":"Real-World Adherence Patterns and Predictors of GLP-1 Receptor Agonist Use for Obesity Management in a Medicaid Population.","authors":"Shadi Bazzazzadehgan, Eric Pittman, Liang-Yuan Lin, Junnan Qi, Amy Ly-Ha, Dennis Smith, Terri Kirby, Tyler A Vest, John P Bentley, Kaustuv Bhattacharya","doi":"10.1007/s12325-026-03806-x","DOIUrl":"https://doi.org/10.1007/s12325-026-03806-x","url":null,"abstract":"<p><strong>Introduction: </strong>Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have emerged as effective anti-obesity medications (AOMs); however, real-world adherence and persistence patterns among Medicaid populations remain poorly understood, specifically after medication shortage resolution. This study examined adherence and persistence to GLP-1 RA AOMs among Mississippi (MS) Medicaid members following statewide coverage initiation in July 2023.</p><p><strong>Methods: </strong>This cohort study utilized MS Medicaid claims data from January 2023 to December 2025. Members aged ≥ 18 years initiating GLP-1 RA AOMs between July 2023 and June 2025, with 6 months of continuous enrollment pre- and post-initiation, were included. Adherence rate was defined as percentage of members with proportion of days covered (PDC) greater than 0.8, and persistence rate was defined as percentage of members with continuous therapy without a 60-day gap, evaluated at 3- and 6-month intervals. Group-based trajectory modeling (GBTM) identified distinct adherence trajectories, and multinomial logistic regression assessed predictors of trajectory membership. A subgroup analysis was conducted for members initiating between July 2023 and December 2024, who had 12-month follow-up period.</p><p><strong>Results: </strong>The final analytic cohort included 3968 members, predominantly female (92.52%), Black (50.28%), and younger adults (18-39 years; 61.95%). Adherence rates declined from 56.85% at 3 months to 38.16% at 6 months, with persistence rates decreasing from 72.98% to 51.03% over the same period. In the 12-month subgroup analysis, adherence and persistence rates declined to 25.26% and 36.67%, respectively. GBTM identified five trajectories: consistent adherent (52.27%), delayed decliner (13.53%), consistent decliner (12.85%), fluctuating adherent (11.14%), and rapid discontinuer (10.21%). Treatment initiation in 2023, younger age, Black race, type 2 diabetes mellitus, and cardiovascular comorbidities were associated with suboptimal adherence trajectories, while managed care organization enrollment and hypertension were protective.</p><p><strong>Conclusion: </strong>GLP-1 RA AOM adherence declines substantially over time among MS Medicaid members. Targeted interventions are needed to sustain long-term therapeutic engagement.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hourly Blood Urea Nitrogen Trajectories and ICU Mortality Risk in Critically Ill Patients with Gastrointestinal Bleeding: A Multicenter Retrospective Cohort Study.","authors":"Bin Liu, Xin Zheng, Zhou Xu, Hai Yan, Yonggang Du, Zhong Yong, Chungen Xing","doi":"10.1007/s12325-026-03796-w","DOIUrl":"https://doi.org/10.1007/s12325-026-03796-w","url":null,"abstract":"<p><strong>Introduction: </strong>Elevated blood urea nitrogen (BUN) is associated with adverse outcomes in gastrointestinal bleeding (GIB), but isolated measurements may not capture early temporal patterns.</p><p><strong>Methods: </strong>A multicenter retrospective cohort study included 5847 adult patients with GIB from four databases (2008-2022). Serial BUN measurements during the first 24 h after ICU admission were mapped to hourly intervals, with at least 12 observed values required. Generalized additive models assessed concentration-duration patterns, adjusted logistic regression evaluated 15 BUN ranges, and restricted cubic splines examined time-weighted BUN. Meta-analysis, measurement-density sensitivity analyses, and static-dynamic model comparisons were performed.</p><p><strong>Results: </strong>Male and female patients comprised 56.5-58.7% and 41.3-43.5% of each cohort,, respectively. ICU mortality ranged from 18.0% to 19.7%. BUN < 30 mg/dL sustained for > 12 h lowered mortality odds (OR: 0.40-0.62), while BUN ≥ 50 mg/dL for >18 h markedly increased them (OR: 1.55-3.39). Prolonged time within 5-30 mg/dL was associated with lower mortality odds, while greater exposure to 40-70 mg/dL increased risk, with no detectable between-database heterogeneity. Associations were nonlinear and remained broadly consistent in denser-measurement subsets. Dynamic models improved AUC from 0.678-0.701 to 0.718-0.748 (all DeLong P ≤ 0.05), with improved reclassification and lower Brier scores.</p><p><strong>Conclusion: </strong>Early dynamic BUN trajectories were associated with ICU mortality and provided incremental prognostic information beyond admission BUN alone. Incorporating both the magnitude and persistence of BUN abnormalities may support early risk stratification in critically ill patients with GIB.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lateral Femoral Cutaneous Nerve Radiofrequency Ablation for the Treatment of Meralgia Paresthetica: A Retrospective Case Series.","authors":"Alaa Abd-Elsayed, Max Y Jin, Barnabas T Shiferaw, Austin P Murphy, Lukas J Henjum","doi":"10.1007/s12325-026-03819-6","DOIUrl":"https://doi.org/10.1007/s12325-026-03819-6","url":null,"abstract":"<p><strong>Introduction: </strong>Meralgia paresthetica is a chronic pain condition that is becoming more common due to increases in obesity and diabetes across the general population. This condition results from damage to or dysfunction of the lateral femoral cutaneous nerve (LFCN). Sensory dysfunction without motor impairment is a hallmark of meralgia paresthetica due to the LFCN being a sensory-only nerve. Symptoms affect the anterolateral to lateral thigh and include pain, tingling, burning, and numbness. Current management options include weight loss, loose clothing, physical therapy, oral medications, corticosteroid injections, and surgery. Radiofrequency ablation (RFA) may be a minimally invasive treatment option used before surgery. Although RFA has demonstrated efficacy for other nerve targets, there is currently insufficient evidence for LFCN RFA. The objective of this retrospective study was to add to the existing evidence by examining the safety and efficacy of thermal LFCN RFA for the treatment of meralgia paresthetica during a short-term follow-up of < 2 months.</p><p><strong>Methods: </strong>This was a single-site retrospective case series that obtained data from electronic medical records of all patients who underwent thermal LFCN RFA between 2014 and 2025. Other RFA types (cooled and pulsed) were excluded. The 10-cm visual analog scale (VAS) was used to assess pain at baseline and post-procedurally. Statistical analysis was performed using a paired t test in SPSS version 30.</p><p><strong>Results: </strong>Thirteen cases involving eight patients were included in this analysis, three of whom underwent the procedure multiple times. VAS scores decreased from 5.77 ± 1.92 to 3.23 ± 2.09 (p = 0.007) after the procedure. A reduction in pain was noted in 9/13 cases. For patients with a reduction in pain, the mean improvement was 62.04%, and pain relief was sustained for 6.43 ± 4.65 months. There were no instances of adverse events.</p><p><strong>Conclusion: </strong>Our study found thermal LFCN RFA to be safe and effective for a high proportion of patients with meralgia paresthetica who have exhausted conservative management options. Future studies should include prospective data, additional parameters, larger sample sizes, and long-term fixed follow-ups.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measuring Hunger Severity in Rare MC4R Pathway Diseases: Development and Psychometric Evaluation of the Most Hunger Item.","authors":"Karine Clément, Christian L Roth, Peter Kühnen, Andrea M Haqq, Usha G Mallya, Claire Ervin, Lindsey Norcross, Sakshi Bhargava, Jesús Argente, Jennifer L Miller","doi":"10.1007/s12325-026-03741-x","DOIUrl":"https://doi.org/10.1007/s12325-026-03741-x","url":null,"abstract":"<p><strong>Introduction: </strong>Leptin receptor (LEPR) deficiency, pro-opiomelanocortin (POMC) deficiency, Bardet-Biedl syndrome (BBS), and acquired hypothalamic obesity (HO) are diseases of the melanocortin 4 receptor (MC4R) pathway that often lead to insatiable hunger and severe obesity. As targeted treatments, such as setmelanotide, emerge for these diseases, it is critical to understand treatment benefit from patients' perspectives. This study describes the development and psychometric evaluation of the Most Hunger item, a patient-reported outcome (PRO) measure assessing hunger in patients with MC4R pathway diseases.</p><p><strong>Methods: </strong>The content validity and appropriateness of the Most Hunger item were evaluated across three separate qualitative interview studies with individuals with LEPR or POMC deficiency, BBS, and acquired HO. Semistructured interviews were conducted. The psychometric evaluation assessed the reliability, validity, responsiveness, and meaningful within-patient change (MWPC) thresholds of the Most Hunger item using responses collected during phase 3 trials of setmelanotide from participants aged ≥12 years with LEPR or POMC deficiency, BBS, or acquired HO.</p><p><strong>Results: </strong>Qualitative interview participants understood the Most Hunger item and could rate their hunger using the item. Hunger scores and patient experiences with hunger were consistent across the three patient populations; patients described an unrelenting hunger prior to treatment and an impactful reduction in hunger post treatment. The Most Hunger item had moderate to good test-retest reliability, and convergent correlations supported its validity. Among patients with LEPR or POMC deficiency, BBS, or acquired HO, MWPC thresholds for Most Hunger (0-10 response scale) were estimated as 1.5-2.6, 0.95-1.6, and 2.4-3.7, respectively.</p><p><strong>Conclusion: </strong>Individuals with these distinct MC4R pathway diseases experience similar and high levels of hunger severity, with behaviors consistent with hyperphagia. The Most Hunger item is a fit-for-purpose PRO measure of hunger to assess treatment benefit in patients aged ≥12 years with LEPR or POMC deficiency, BBS, or acquired HO.</p><p><strong>Trial registrations: </strong>ClinicalTrials.gov identifiers, NCT03287960, NCT02896192, NCT03746522, and NCT05774756.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Experience with Treatment of HAE Attacks: Results from a Real-World Survey of Physicians and Their Patients.","authors":"John Anderson, Laurence Bouillet, Paula J Busse, Teresa Caballero, Mar Guilarte, Michihiro Hide, Ramón Lleonart, William R Lumry, Markus Magerl, Marc A Riedl, Patrick F K Yong, Andrea Zanichelli, Hannah Connolly, Maggie Chen, Joan Mendivil","doi":"10.1007/s12325-026-03790-2","DOIUrl":"https://doi.org/10.1007/s12325-026-03790-2","url":null,"abstract":"<p><strong>Introduction: </strong>Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent, unpredictable, and potentially life-threatening angioedema attacks. Few reports describing physician and patient perspectives on their experiences with HAE, long-term prophylaxis (LTP), and on-demand treatment regimens exist. This analysis aimed to address remaining critical gaps, particularly regarding patient attitudes toward treatment adherence, symptom experience, and timing to relief onset, by capturing physician and patient insights on these topics.</p><p><strong>Methods: </strong>Data are from the Adelphi Real World HAE Disease Specific Programme™, a cross-sectional, retrospective survey of physicians and their patients conducted across Europe, Japan, and the US from January 2023 through January 2024. Surveyed physicians were directly involved in the management of at least two patients with HAE per month. Eligible patients had experienced at least one attack since diagnosis. Physicians completed an online Patient Record Form (PRF) based on data from patients' medical charts and their clinical judgment. Each patient with a physician-completed form was invited to complete a voluntary self-reported questionnaire.</p><p><strong>Results: </strong>Participating physicians (n = 225) completed PRFs for 1131 patients (age range: 3-82 years); 279 patients completed the questionnaire. Most patients were female (physician reported: 607/1131 [54%]; patient reported: 145/279 [52%]). Overall, 48% of patients in the physician-reported groups and 51% in the patient-reported group experienced one to two attacks during the 12 months before the survey. The top reason for not treating the most recent attack was perceiving it as mild/not severe or limiting (physician reported: 54%; patient reported: 59%). The top reason for suboptimal adherence to LTP in the physician- and patient-reported groups was forgetting to take medication (45% and 51%, respectively).</p><p><strong>Conclusion: </strong>This analysis increases our understanding of the lived experience of HAE and helps address the remaining gaps in treatment satisfaction and adherence within the HAE community.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians.","authors":"Rahul Banerjee, Hamza Hashmi, Preet M Chaudhary, Shebli Atrash, Kimberly Green, Sabyasachi Ghosh, Todd Bixby, Denise De Wiest, Matthew Perciavalle, David H Vesole, Forat Lutfi, Waqas Jehangir, Gurbakhash Kaur, Adeel M Khan, Rahma Warsame, Ashwathi Puravankara Menon, Mark A Price, Guru Subramanian Guru Murthy, Danai Dima, Brian J Carney, Zaina P Qureshi, Saurabh Chhabra","doi":"10.1007/s12325-026-03794-y","DOIUrl":"https://doi.org/10.1007/s12325-026-03794-y","url":null,"abstract":"","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-Indication Budget Impact Analysis of Subcutaneous IgPro20 Pre-filled Syringes for the Treatment of Primary Immunodeficiency Syndromes, Secondary Immunodeficiencies, and Chronic Inflammatory Demyelinating Polyneuropathy in Italy.","authors":"Batyrkhan Kuatov, Alanna MacDonald, Stacey Priest, Diana Tran, Laurence Undreiner, Melike Inkaya Taskin, Sara Villa, Andrea Marcellusi","doi":"10.1007/s12325-026-03805-y","DOIUrl":"https://doi.org/10.1007/s12325-026-03805-y","url":null,"abstract":"<p><strong>Introduction: </strong>Primary immunodeficiency (PID) and secondary immunodeficiency (SID) are chronic conditions associated with impaired immune function and increased susceptibility to infections. Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune neurological disorder characterized by progressive motor and sensory deficits due to immune-mediated demyelination of peripheral nerves. Patients with these diseases often require long-term immunoglobulin (IG) therapy, which can be costly and burdensome, particularly when administered intravenously in hospital settings. IgPro20 pre‑filled syringes (PFS) offer a simplified, subcutaneous IG alternative that may reduce treatment burden and improve cost‑efficiency. The aim of this study was to estimate the budget impact of introducing IgPro20 PFS into the Italian healthcare system for patients with PID, SID, and CIDP.</p><p><strong>Methods: </strong>A population-based budget impact model was developed in Microsoft Excel® from the perspective of the Italian National Health Service (Servizio Sanitario Nazionale). The model used a 3-year time horizon and incorporated drug acquisition, administration, and adverse event costs. Model comparators included intravenous and subcutaneous IG and IgPro20 vials. Population estimates and market shares were informed by Italian affiliates.</p><p><strong>Results: </strong>The introduction of IgPro20 PFS resulted in total cost savings of €31,524,488 for 4794 patients over 3 years. Savings were distributed across PID (€8,840,041), SID (€5,413,035), and CIDP (€17,271,412). Sensitivity analyses identified IgPro20 PFS and vial pricing as key drivers.</p><p><strong>Conclusion: </strong>IgPro20 PFS are a cost-saving, patient-centric treatment option for PID, SID, and CIDP. These findings support their adoption in Italy's healthcare system and may inform policy and payer decisions at regional and national levels.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern.","authors":"Theocharis Koufakis, Anastasios Tentolouris, Paschalis Karakasis, Djordje S Popovic, Dimitrios Patoulias","doi":"10.1007/s12325-026-03804-z","DOIUrl":"https://doi.org/10.1007/s12325-026-03804-z","url":null,"abstract":"<p><p>The introduction of highly effective incretin-based therapies has transformed obesity management by achieving weight loss previously attainable mainly with bariatric surgery. However, the accompanying reduction in lean body mass has raised concerns regarding treatment-induced sarcopenia, particularly among older adults and other vulnerable populations. In this perspective, we argue that interpreting lean mass loss in isolation may be misleading. Current evidence indicates that approximately one-quarter to one-third of total weight loss consists of lean mass, a proportion comparable to that observed with other effective weight-loss interventions and consistent with physiological body composition remodeling rather than pathological muscle loss. Importantly, incretin therapies preferentially reduce fat mass, improve the lean-to-fat mass ratio, and are associated with improvements in physical function, mobility, and health-related quality of life. These observations challenge the assumption that reductions in lean body mass necessarily translate into clinically meaningful sarcopenia. Nevertheless, skeletal muscle health deserves particular attention in older adults and individuals with pre-existing sarcopenia, frailty, chronic kidney or cardiovascular disease, chronic inflammatory conditions, or poor nutritional status. In these populations, routine assessment of muscle strength and physical performance, together with adequate protein intake and structured resistance exercise, should complement pharmacological obesity treatment. Future research should prioritize muscle quality and function rather than lean mass alone to better define the clinical significance of body composition changes during incretin therapy.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Characteristics and Treatment Patterns of Advanced Biliary Tract Cancer (BTC): A Chinese Physician Survey.","authors":"Hui Qiu, Qiao Liu, Zhen Wang, Wenting Chen, Wenmin Tang, Chunyi Hao","doi":"10.1007/s12325-026-03732-y","DOIUrl":"https://doi.org/10.1007/s12325-026-03732-y","url":null,"abstract":"<p><strong>Introduction: </strong>Biliary tract cancers (BTCs) encompass rare malignancies arising from bile duct and gallbladder epithelial cells. This study investigated Chinese physicians' understanding of advanced BTC including patient characteristics, treatment patterns, and decision-making factors in clinical practice.</p><p><strong>Methods: </strong>A survey of 120 randomly selected physicians who currently treat patients with advanced BTC was conducted between September 19, 2024 and November 4, 2024.</p><p><strong>Results: </strong>Of the 120 total respondents, 48 were surgeons, 48 were oncologists, and 24 were interventionalists or radiotherapists. The respondents indicated that over half of patients (58.2%) are initially deemed to have unresectable tumors. Physicians estimated that 77.3% of patients with advanced BTC receive first-line therapy, most commonly with immunotherapy plus chemotherapy (34.2%), chemotherapy alone (15.8%), or local-regional combination therapies (10.8%). The most commonly used immunotherapy plus chemotherapy regimen is gemcitabine and cisplatin plus immunotherapy followed by gemcitabine plus oxaliplatin plus immunotherapy. Following progression on first-line therapy, physicians indicated 43.8% of patients proceed to subsequent treatment, most commonly with immunotherapy plus chemotherapy (23.3%), chemotherapy (12.5%), or immunotherapy plus anti-angiogenic agent (11.7%). The average physician satisfaction scores for current treatment and management of advanced BTC were between 6.1 and 7.5 out of 10. The key challenges indicated by respondents in treating patients with advanced BTC were limited selection of treatment regimens (46.7%) and financial barriers to care (40.0%).</p><p><strong>Conclusion: </strong>This is the first study to report Chinese physicians' understanding of patient characteristics and treatment patterns for advanced BTC, providing valuable insights which will inform advanced BTC treatment in China.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Registry identifier, ChiCTR2400087092.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives on Living with Relapsed/Refractory Multiple Myeloma and Multidisciplinary Care from a Patient, Nurse Practitioner, Dietitian, and a Patient Advocate.","authors":"Becky Bosley, Isabelle Wlodkowski, Donna Catamero, Sarah Meredith","doi":"10.1007/s12325-026-03801-2","DOIUrl":"https://doi.org/10.1007/s12325-026-03801-2","url":null,"abstract":"<p><p>Multiple myeloma is a malignant hematologic disorder characterized by the proliferation of abnormal plasma cells in the bone marrow. Although improvements in survival as novel therapies have become available, almost all patients who receive multiple myeloma therapies will relapse. Patients experience physical and emotional impacts from both multiple myeloma and its treatment as they progress through periods of remission and relapse. It is essential to support patients throughout their disease with holistic management, underpinned by collaboration among the clinical team and emotional support resources, including access to patient support groups. This article is co-authored by a person living with multiple myeloma, along with a dietitian specializing in cancer dietetics, a nurse practitioner who cares for patients with multiple myeloma at a large academic center, and a patient advocate at the International Myeloma Foundation. Written from a first-person perspective, the patient describes her journey of living with multiple myeloma and her current treatment with talquetamab, with added perspectives from clinical and patient advocacy experts.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}